Related Experiment Videos
Disease modification: promising targets and impediments to success
1Orthopaedic & Regenerative Medicine Research, Genzyme, A Sanofi Company, Framingham, MA 01701, USA. gloria.matthews@sanofi.com
Rheumatic Diseases Clinics of North America
|January 15, 2013
Summary
Effective treatments for osteoarthritis (OA) are lacking. This review discusses challenges in developing disease-modifying OA drugs and explores current therapeutic strategies.
Area of Science:
- Rheumatology
- Pharmacology
- Drug Development
Background:
- Osteoarthritis (OA) affects a large population and lacks disease-modifying treatments.
- Significant investment has not yielded effective therapies to slow OA progression.
- The cartilage-centric view may have limited progress in OA research.
Purpose of the Study:
- To review the challenges in developing disease-modifying osteoarthritis drugs (DMO-ADs).
- To identify and discuss current and emerging therapeutic intervention strategies for OA.
Main Methods:
- Literature review of OA pathophysiology and drug development.
- Analysis of recent clinical trials and therapeutic approaches for OA.
- Discussion of target selection and development hurdles.
Main Results:
- No effective disease-modifying OA treatments are currently available.
- Target selection for OA therapies remains a significant challenge.
- Novel therapeutic strategies are being explored but face development hurdles.
Conclusions:
- Developing disease-modifying drugs for osteoarthritis is complex.
- Overcoming the cartilage-centric view and addressing development challenges are crucial.
- Exploring diverse therapeutic strategies is essential for future OA treatment advancements.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...